CCX559 is a potent, orally-administered small molecule PD-L1 inhibitor that induces anti-tumor immunity

The interaction of PD-L1 with PD-1 is a major immune checkpoint that limits effector T cell function against cancer cells; monoclonal antibodies that block this pathway have been approved in multiple tumor indications. As a next generation therapy, small molecule inhibitors of PD-L1 have inherent dr...

Descripción completa

Detalles Bibliográficos
Autores principales: Sullivan, Kathleen M. C., Vilalta, Marta, Ertl, Linda S., Wang, Yu, Dunlap, Carolyn, Ebsworth, Karen, Zhao, Bin N., Li, Shijie, Zeng, Yibin, Miao, Zhenhua, Fan, Pingchen, Mali, Venkat, Lange, Christopher, McMurtrie, Darren, Yang, Ju, Lui, Rebecca, Scamp, Ryan, Chhina, Vicky, Kumamoto, Alice, Yau, Simon, Dang, Ton, Easterday, Ashton, Liu, Shirley, Miao, Shichang, Charo, Israel, Schall, Thomas J., Zhang, Penglie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10246841/
https://www.ncbi.nlm.nih.gov/pubmed/37285333
http://dx.doi.org/10.1371/journal.pone.0286724

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10246841/
https://www.ncbi.nlm.nih.gov/pubmed/37285333
http://dx.doi.org/10.1371/journal.pone.0286724

Ejemplares similares